

<i>Patient Number</i>	<i>Age</i>	<i>Onset of Symptoms</i>	<i>Years Affected</i>	<i>Severity</i>	<i>Gender</i>	<i>Dosage Regimen</i>	<i>BMI</i>
1	76	22	52	Severe	F	L	24.4
2	79	50	29	Severe	F	H	23.5
3	53	15	38	Severe	M	H	19.8
4	52	21	21	Severe	F	L	24.0
5	57	18	39	Mild	F	H	23.2
6	54	22	32	Severe	F	H	35.5
7	55	20	35	Severe	M	L	22.1
8	60	52	8	Severe	M	H	28.5
9	57	44	13	Mild	F	L	25.0
10	48	18	30	Moderate	F	L	22.3
11	34	18	16	Moderate	M	L	24.4
12	36	25	11	Moderate	F	H	24.9
13	30	17	13	Moderate	F	H	26.6
14	24	20	4	Moderate	F	L	22.1

Supplemental Table. Characteristics of human HSAN1 patients enrolled in the pilot study of L-serine. Age is listed in years. All patients carried the *SPTLC1*-C133Y mutation and were treated with either low dose (L: 200mg/kg/d) or high dose (H: 400mg/kg/d) L-serine. Randomization to high or low dose was stratified by disease severity (mild/moderate versus severe) and gender. “Mild” was defined as sensory symptoms only, “moderate” as requiring ankle-foot orthoses and “severe” as requiring a cane or walker. BMI = body mass index.